Lund­beck-part­nered pre­clin­i­cal biotech nabs Se­ries A from As­traZeneca

Cam­bridge, MA biotech Rgen­ta Ther­a­peu­tics has se­cured $52 mil­lion in a Se­ries A to take oral small mol­e­cules in­to the clin­ic.

The 20-per­son biotech, which is al­ready al­lied with Lund­beck, looks to ink more phar­ma part­ner­ships with­in its core ar­eas of on­col­o­gy and neu­ro­science rare dis­eases, as well as in oth­er dis­ease ar­eas the start­up thinks the RNA-tar­get­ing plat­form can go, CSO Travis Wa­ger told End­points News ahead of the Tues­day morn­ing news.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER